Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Bristol Myers Squibb has agreed to pay up to $3 billion to discover and develop new cancer drugs based on a concept known as synthetic lethality, in which the…
Bristol Myers Squibb agreed to pay Canada's Repare Therapeutics up to $3 billion to develop synthetic lethal cancer drugs, the companies said on Thursday.…
Repare Therapeutics reported initial Phase 1 efficacy data for lead ATR inhibitor camonsertib (RP-3500) in patients with ATM and BRCA-mutant solid tumors, with…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Bristol-Myers Squibb and Repare Therapeutics entered a global research collaboration and license agreement to discover, develop and commercialize novel synthetic lethality precision oncology drug candidates. Repare received $50M cash + $15M equity upfront and is eligible for up to ~$3B in license, discovery, development, regulatory and sales milestones plus royalties.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Repare Therapeutics Inc. (this deal) | 2020 | $3.1B | — |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2020 deals · Bristol-Myers Squibb Company deals · Oncology deals